Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for concurrent use with PD-1/PD-L1 i
Novocure wins FDA nod for lung cancer treatment wearable
Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung cancer.
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
NovoCure's Optune Lua, a tumor-treating fields device, gains FDA approval for use with PD-1/PD-L1 inhibitors or docetaxel in metastatic non-small cell lung cancer patients, demonstrating significant survival benefits.
NovoCure scoops FDA approval on wearable for metastatic cancer treatment
Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS improvement.
Novocure nets FDA approval for Tumor Treating Fields in metastatic lung cancer
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small cell lung cancer—which the company described as the first tre | Novocure described its Tumor Treating Fields therapy as the first of its kind for the aggressive cancer,
Novocure shares soar 33% as FDA approves lung cancer treatment
Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable device designed to treat certain types of lung cancer. The stock surged more than 33% in premarket
Novocure wins FDA approval for electric field device in lung cancer
Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.
Novocure shares surge on cancer treatment approval, and other movers
Novocure shares are surging 35% after the company said that the [Food and Drug Administration had approved Optune Lua](
The American Journal of Managed Care
1d
FDA Approves Optune Lua Device in NSCLC
Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...
Targeted Oncology
1d
FDA Oks Optune Lua for Use With PD-1/PD-L1 Inhibitors in Metastatic NSCLC
Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...
1d
NovoCure’s Optune Lua Gains FDA Approval for NSCLC, Projecting Significant Sales Growth and Expansion
H.C. Wainwright analyst Emily Bodnar upgraded the rating on NovoCure (NVCR – Research Report) to a Buy today, setting a price target of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Preliminary cause of death
Panel calls for 'reform'
Hamas leader Sinwar killed
Retiring after 15 seasons
School shooting indictment
Donations drop 15%
Sells for $9M at auction
Evidence delay bid denied
Musk's first Trump event
Texas AG sues doctor
988 Lifeline georouting
US charges ex-Indian spy
TX top court halts execution
Receives SEC subpoena
Warns on 'untargeted tariffs'
Teen tobacco use falls
Sued for alleged misconduct
Dow closes at record high
FTC probing Deere
Afghan man denied release
Teen anti-sextortion push
Colsen fire pits recalled
Space export curbs eased
Hyundai recalls vehicles
Files for US IPO
To open Epic Universe
Bleaching event expands
Mutual HIV transplants safe
‘South Pacific' star dies
DA aims to revive charges
May help with addiction too
Feedback